Find Tezacaftor manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Vx-661, 1152311-62-0, Tezacaftor (vx-661), Tezacaftor [usan], (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide, Vx661
Molecular Formula
C26H27F3N2O6
Molecular Weight
520.5  g/mol
InChI Key
MJUVRTYWUMPBTR-MRXNPFEDSA-N
FDA UNII
8RW88Y506K

Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition.
1 2D Structure

Tezacaftor

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
2.1.2 InChI
InChI=1S/C26H27F3N2O6/c1-24(2,13-33)22-8-14-7-18(17(27)10-19(14)31(22)11-16(34)12-32)30-23(35)25(5-6-25)15-3-4-20-21(9-15)37-26(28,29)36-20/h3-4,7-10,16,32-34H,5-6,11-13H2,1-2H3,(H,30,35)/t16-/m1/s1
2.1.3 InChI Key
MJUVRTYWUMPBTR-MRXNPFEDSA-N
2.1.4 Canonical SMILES
CC(C)(CO)C1=CC2=CC(=C(C=C2N1CC(CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
2.1.5 Isomeric SMILES
CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F
2.2 Other Identifiers
2.2.1 UNII
8RW88Y506K
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Vx-661

2.3.2 Depositor-Supplied Synonyms

1. Vx-661

2. 1152311-62-0

3. Tezacaftor (vx-661)

4. Tezacaftor [usan]

5. (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide

6. Vx661

7. Vx 661

8. 8rw88y506k

9. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide

10. Unii-8rw88y506k

11. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide

12. Cv6

13. Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)-

14. Tezacaftor [mi]

15. Tezacaftor [inn]

16. Tezacaftor (usan/inn)

17. Tezacaftor [who-dd]

18. Schembl322362

19. Vx 661;vx661;tezacaftor

20. Chembl3544914

21. Schembl10034144

22. Tezacaftor [orange Book]

23. Gtpl10199

24. Dtxsid40673070

25. Bdbm281054

26. Symkevi Component Tezacaftor

27. Bcp07173

28. Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl]-

29. Ex-a1759

30. Trikafta Component Tezacaftor

31. Mfcd23106064

32. S7059

33. Us10022352, Compound 315

34. Zinc68206930

35. Ccg-269854

36. Cs-1078

37. Db11712

38. Tezacaftor Component Of Trikafta

39. 1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide

40. Ac-32773

41. As-35211

42. Hy-15448

43. Example 315 [us20090131492a1]

44. Sw219937-1

45. D11041

46. A857959

47. Q27270940

48. (r)-1 (2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide

49. (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropane-1-carboxamide

50. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-~{n}-[1-[(2~{r})-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide

51. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)cyclopropanecarboxamide

52. 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl]-cyclopropanecarboxamide

53. Vx661; Vx 661; Tezacaftor;(r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide

2.4 Create Date
2010-07-06
3 Chemical and Physical Properties
Molecular Weight 520.5 g/mol
Molecular Formula C26H27F3N2O6
XLogP32.9
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count9
Rotatable Bond Count8
Exact Mass520.18212107 g/mol
Monoisotopic Mass520.18212107 g/mol
Topological Polar Surface Area113 Ų
Heavy Atom Count37
Formal Charge0
Complexity858
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Tezacaftor is combined with ivacaftor in one product for the treatment of cystic fibrosis (CF) in patients aged 12 years or older with two copies of the _F508del_ gene mutation or at least one mutation in the CFTR gene that is responsive to this drug. Tezacaftor, when used in combination with ivacaftor and [elexacaftor] in the product Trikafta, is also indicated for the treatment of CF in patients 12 years of age and older that have at least one _F508del_ mutation in the CFTR gene.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Clinical studies have shown a significant decrease in sweat chloride and an increase in the forced expiratory volume (FEV), a measure of lung function, following Tevacaftor/Ivacaftor therapy. Phase 3 clinical studies have shown that a significant increase in forced expiratory volume was attained at 4 and 8 weeks after initiating this drug. The above effects lead to improvement of the respiratory symptoms of cystic fibrosis. Tezacaftor does not induce clinically significant QT prolongation. When given with ivacaftor, tezacaftor can lead to liver transaminase elevations. Testing of transaminases (ALT and AST) levels should occur before starting this combination every 3 months during the first year of treatment, and every year afterwards. Patients with a history of transaminase elevations should be monitored more frequently.


5.2 Absorption, Distribution and Excretion

Absorption

The Cmax, Tmax and AUC of tezacaftor, when administered with ivacaftor, are 5.95 mcg/ml, 2-6 h, and 84.5 mcg.h/ml respectively. Exposure of tezacaftor/ivacaftor increases 3-fold when it is administered with a high-fat meal.


Route of Elimination

After oral administration, the majority of tezacaftor dose (72%) is found excreted in the feces either unchanged or as its metabolite, M2. About 14% of the administered dose is found excreted in the urine as the metabolite, M2. It was noted that less than 1% of the administered dose is excreted unchanged in the urine and thus, renal excretion is not the major elimination pathway.


Volume of Distribution

The apparent volume of distribution of tezacaftor was 271 L in a study of patients in the fed state who received 100 mg of tezacaftor every 12 hours.


Clearance

The apparent clearance of tezacaftor has been measured at 1.31 L/h for patients in the fed state during a clinical trial.


5.3 Metabolism/Metabolites

Tezacaftor is metabolized extensively in humans by the action of CYP3A4 and CYP3A5. There are three main circulating metabolites; M1, M2, and M5. The M1 is an active metabolite with similar activity to the parent drug, tezacaftor. The M2 metabolite is significantly less active and M5 is considered an inactive metabolite. An additional circulating metabolite, M3, corresponding to the glucuronide form of tezacaftor.


5.4 Biological Half-Life

The apparent half-life of tezacaftor is approximately 57.2 hours.


5.5 Mechanism of Action

The transport of charged ions across cell membranes is normally achieved through the actions of the cystic fibrosis transmembrane regulator (CFTR) protein. This protein acts as a channel and allows for the passage of chloride and sodium. This process affects the movement of water in and out of the tissues and impacts the production of mucus that lubricates and protects certain organs and body tissues, including the lungs. In the _F508del_ mutation of the CFTR gene, one amino acid is deleted at the position 508, therefore, the CFTR channel function is compromised, resulting in thickened mucus secretions. CFTR correctors such as tezacaftor aim to repair F508del cellular misprocessing. This is done by modulating the position of the CFTR protein on the cell surface to the correct position, allowing for adequate ion channel formation and increased in water and salt movement through the cell membrane. The concomitant use of ivacaftor is intended to maintain an open channel, increasing the transport of chloride, reducing thick mucus production.


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

02

HRV Global Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

03

Medichem S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Medichem

04

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

05

Laurus Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

06

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Prague Scientific

Czech Republic

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

08

ScinoPharm Taiwan, Ltd

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

TEZACAFTOR

NDC Package Code : 59651-618

Start Marketing Date : 2024-01-19

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (40kg/50kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

TEZACAFTOR

NDC Package Code : 57572-0724

Start Marketing Date : 2024-04-19

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

TEZACAFTOR

NDC Package Code : 57572-0719

Start Marketing Date : 2021-05-05

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

TEZACAFTOR

NDC Package Code : 50909-1903

Start Marketing Date : 2021-02-08

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (0.8kg/kg)

Marketing Category : DRUG FOR FURTHER PROCESSING

blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

TEZACAFTOR

NDC Package Code : 24538-661

Start Marketing Date : 2018-02-12

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Tezacaftor

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content

Tezacaftor

About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...

HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It offers services such as sourcing, manufacturing & supply, helping partners enter new markets worldwide. Its strong partnerships with major players in the pharma and food additive industries help HRV Global effectively promote projects and products. HRV Global represents over 30 large Indian drugmakers, primarily targeting Europe, the US & the Middle East markets. Headquartered in India, HRV Global has offices in the US, Switzerland, Dubai, Lithuania & Turkey.
HRV Global Life Sciences

03

Medichem S.A

Spain
arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content

Tezacaftor

About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...

Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Active Pharmaceutical Ingredients (APIs), including Highly Potent. In 2016, Medichem merged with Combino Pharm, which is devoted to the development and manufacture (licensing) of Finished Dosage Forms. With this merger, Medichem has become a vertically integrated pharmaceutical company which can offer a complete range of products and services for the pharmaceutical industry with the highest standards of quality, operational excellence and environment respect.
Medichem

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Tezacaftor

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

05

Hetero Drugs

India
BIO Partnering at JPM
Not Confirmed
arrow

Hetero Drugs

India
arrow
BIO Partnering at JPM
Not Confirmed

Tezacaftor

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

06

Laurus Labs

India
BIO Partnering at JPM
Not Confirmed
arrow

Laurus Labs

India
arrow
BIO Partnering at JPM
Not Confirmed

Tezacaftor

About the Company : Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Ph...

Laurus Labs is a leading research and development-driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Out of Ten largest generic pharmaceutical companies in the world, by revenues, are our customers.
blank

07

Prague Scientific

Czech Republic
BIO Partnering at JPM
Not Confirmed
arrow

Prague Scientific

Czech Republic
arrow
BIO Partnering at JPM
Not Confirmed

Tezacaftor

About the Company : Prague Scientific has decades of experience in developing, producing and distributing medicines. It is a cost leader in urology, cardiology, oncology and pain products, with specia...

Prague Scientific has decades of experience in developing, producing and distributing medicines. It is a cost leader in urology, cardiology, oncology and pain products, with specialization in solids, hormones and sterile products. Prague Scientific offers services across development, regulatory and pharmacovigilance. With facilities in Prague (the Czech Republic), Bucharest (Romania) and Ankleshwar (India), it transfers over 80 products per year and benefits from a global regulatory experience. It works with clients through dedicated and cross-functional teams to meet specific needs.
blank

08

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Tezacaftor

About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...

ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry.Combining cost-effective resources and productivity of Asia along with unmatched regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.


Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor

Therapeutic Area: Genetic Disease Brand Name: VX-121

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 02, 2024

blank

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.

Brand Name : VX-121

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 02, 2024

blank

Details:

VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.


Lead Product(s): Vanzacaftor,Tezacaftor,Deutivacaftor

Therapeutic Area: Genetic Disease Brand Name: VX-121

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2024

blank

02

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : VX-121/VX-661/VX-561 (vanzacaftor/tezacaftor/deutivacaftor) is a combination of three CFTR modulators. It is being evaluated in phase 3 clinial trials for the treatment of Cystic Fibrosis.

Brand Name : VX-121

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 05, 2024

blank

Details:

Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2023

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 24, 2023

blank

Details:

Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2023

blank

04

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 23, 2023

blank

Details:

Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein at the cell surface.


Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2023

blank

05

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein a...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2023

blank

Details:

TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is prescription medicine for treatment of cystic fibrosis. Based on analysis through Week 144 of 192-week study, people receiving TRIKAFTA maintained improvement in lung function, respiratory symptom and CFTR function.


Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

blank

06

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), is prescription medicine for treatment of cystic fibrosis. Based on analysis through Week 144 of 192-week study, people receiving TRIKAFTA maintained improvement in lung function, respiratory sym...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 03, 2022

blank

Details:

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF).


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2022

blank

07

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fi...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 10, 2022

blank

Details:

TRIKAFTA is an oral medicine designed to increase quantity and function of CFTR protein at cell surface, is a prescription medicine used for treatment of cystic fibrosis in patients ages 6 years and older who have at least one copy of F508del mutation in CFTR gene.


Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2022

blank

08

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : TRIKAFTA is an oral medicine designed to increase quantity and function of CFTR protein at cell surface, is a prescription medicine used for treatment of cystic fibrosis in patients ages 6 years and older who have at least one copy of F508del mutation in...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 20, 2022

blank

Details:

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) was approved by the Australian Therapeutic Goods Administration (TGA) in March 2021 based on the results of four global Phase 3 clinical trials, which included multiple Australian trial sites and patients.


Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Australian Pharmaceutical Benefits Scheme

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 27, 2022

blank

09

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) was approved by the Australian Therapeutic Goods Administration (TGA) in March 2021 based on the results of four global Phase 3 clinical trials, which included multiple Australian trial sites an...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 27, 2022

blank

Details:

EC approval for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor has shown clinical benefit for people with CF ages 12 and above. This medicine is also approved in the regulatory authorities of New Zealand and Switzerland, where it is known as TRIKAFTA.


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2022

blank

10

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : EC approval for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor has shown clinical benefit for people with CF ages 12 and above. This medicine is also approved in the regulatory authorities of New Zealand and Switzerland, where i...

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 11, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

LinkChem

China
Duphat
Not Confirmed
arrow

LinkChem

China
Duphat
Not Confirmed
arrow

CAS Number : 952664-69-6

End Use API : Tezacaftor

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank

02

LinkChem

China
Duphat
Not Confirmed
arrow

LinkChem

China
Duphat
Not Confirmed
arrow

CAS Number : 3587-60-8

End Use API : Tezacaftor

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank

03

LinkChem

China
Duphat
Not Confirmed
arrow

LinkChem

China
Duphat
Not Confirmed
arrow

CAS Number : 5272-33-3

End Use API : Tezacaftor

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Ivakaftor; Tezakaftor; Eleksakaftor

Brand Name : Cafe trio

Dosage Form : Granules in a dose bag

Dosage Strength : 75 mg/50 mg/100 mg

Packaging : Dosepose 4 7item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Ivakaftor; Tezakaftor; Eleksakaftor

Brand Name : Cafe trio

Dosage Form : Granules in a dose bag

Dosage Strength : 60 mg/40 mg/80 mg

Packaging : Dosepose 4 7item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Elexacaftorum; Tezacaftorum; Ivacaftorum

Brand Name : Trikafta

Dosage Form : Filmtabl

Dosage Strength : 100mg/50mg/75mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

04

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Elexacaftorum; Tezacaftorum; Ivacaftorum

Brand Name : Trikafta

Dosage Form : Filmtabl

Dosage Strength : 50mg/25mg/37.5mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

Tezacaftorum; Ivacaftorum

Brand Name : Symdeko

Dosage Form : Filmtabl

Dosage Strength : 100mg/150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Tezacaftor Manufacturers

A Tezacaftor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tezacaftor, including repackagers and relabelers. The FDA regulates Tezacaftor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tezacaftor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Tezacaftor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Tezacaftor Suppliers

A Tezacaftor supplier is an individual or a company that provides Tezacaftor active pharmaceutical ingredient (API) or Tezacaftor finished formulations upon request. The Tezacaftor suppliers may include Tezacaftor API manufacturers, exporters, distributors and traders.

click here to find a list of Tezacaftor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Tezacaftor USDMF

A Tezacaftor DMF (Drug Master File) is a document detailing the whole manufacturing process of Tezacaftor active pharmaceutical ingredient (API) in detail. Different forms of Tezacaftor DMFs exist exist since differing nations have different regulations, such as Tezacaftor USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Tezacaftor DMF submitted to regulatory agencies in the US is known as a USDMF. Tezacaftor USDMF includes data on Tezacaftor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tezacaftor USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Tezacaftor suppliers with USDMF on PharmaCompass.

Tezacaftor NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tezacaftor as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Tezacaftor API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Tezacaftor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Tezacaftor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tezacaftor NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Tezacaftor suppliers with NDC on PharmaCompass.

Tezacaftor GMP

Tezacaftor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tezacaftor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tezacaftor GMP manufacturer or Tezacaftor GMP API supplier for your needs.

Tezacaftor CoA

A Tezacaftor CoA (Certificate of Analysis) is a formal document that attests to Tezacaftor's compliance with Tezacaftor specifications and serves as a tool for batch-level quality control.

Tezacaftor CoA mostly includes findings from lab analyses of a specific batch. For each Tezacaftor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tezacaftor may be tested according to a variety of international standards, such as European Pharmacopoeia (Tezacaftor EP), Tezacaftor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tezacaftor USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty